DR. DANIEL J TANNER, M.D.
Dermatology at 55 St, Brooklyn, NY
License number
New York 118399
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
1401 55Th St, Brooklyn, NY 11219
Phone
(718) 851-8737
Personal information
See more information about DANIEL J TANNER at radaris.comName
Address
Phone
375 S End Ave APT 14K, New York, NY 10280
139 Culver Pkwy, Rochester, NY 14609
224 Dogwood Ln, Hartsdale, NY 10530
Professional information
Dr. Daniel J Tanner, Brooklyn NY - MD (Doctor of Medicine)
Specialties:
Dermatology
Address:
1401 55Th St, Brooklyn 11219
(718) 851-8737 (Phone)
(718) 851-8737 (Phone)
Certifications:
Dermatology, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 1972
Mount Sinai Hospital
Einstein
New York University
Graduated: 1972
Mount Sinai Hospital
Einstein
Treatment Of Squamous Cell Carcinoma Intralesionally With Recombinant Human Alpha Interferon
US Patent:
5256410, Oct 26, 1993
Filed:
May 20, 1991
Appl. No.:
7/684964
Inventors:
Daniel J. Tanner - Brooklyn NY
Edwin A. Peets - New York NY
Kenneth A. Smiles - Novato CA
Edwin A. Peets - New York NY
Kenneth A. Smiles - Novato CA
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 3766
US Classification:
424 857
Abstract:
Human squamous cell carcinoma is successfully treated by intralesional administration of recombinant human interferon alpha-2b.
Treatment Of Genital Warts With A Combination Of Liquid Nitrogen And Recombinant Dna Human Alpha Interferon
US Patent:
4959210, Sep 25, 1990
Filed:
Nov 1, 1988
Appl. No.:
7/265612
Inventors:
Kenneth A. Smiles - Windsor NJ
Edwin A. Peets - New York NY
Daniel J. Tanner - Brooklyn NY
Edwin A. Peets - New York NY
Daniel J. Tanner - Brooklyn NY
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 3766
US Classification:
424 857
Abstract:
Condylomata Acuminata infections (anogenital warts) are treated in infected patients by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks.
The interferon exemplified is recombinant DNA human interferon alfa-2b in which 1. times. 10. sup. 6 International Units are administered by injection to each lesion.
The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means.
Treatment Of Actinic Keratoses With Alpha.sub.2 Interferon
US Patent:
5002764, Mar 26, 1991
Filed:
Aug 22, 1989
Appl. No.:
7/397365
Inventors:
Edwin A. Peets - New York NY
Kenneth A. Smiles - East Windsor NJ
Daniel J. Tanner - Brooklyn NY
Kenneth A. Smiles - East Windsor NJ
Daniel J. Tanner - Brooklyn NY
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 3766
US Classification:
424 857
Abstract:
A method of treating actinic keratoses with alpha. sub. 2 interferon is disclosed.